Biotechnology

International Perinatal Stem Cell Society Calls for Updated U.S. Regulatory Framework for Stem Cell and Tissue Products

August 6, 2024 5:50 PM

The International Perinatal Stem Cell Society has released a position paper advocating for changes to the U.S. regulatory landscape for perinatal stem cell and tissue products. The Society argues that while FDA guidance has driven innovation in the past, the current regulatory framework is now holding back advancements in regenerative medicine. The Society believes that these changes will help restore the U.S. as a global leader in regenerative...

Read more

Vibrant Wellness Improves Turnaround Times for Key Lab Tests

August 6, 2024 9:30 AM

SANTA CLARA, CA / ACCESSWIRE / August 6, 2024 / Vibrant Wellness, a leading CLIA-certified and CAP-accredited lab, is excited to announce significant reductions in turnaround times for several of its core lab tests. This milestone underscores Vibrant's commitment to improving healthspan and longevity by enabling earlier, targeted detection of challenging health conditions. Rapid Turnaround Times for Earlier Interventions While many competitors...

Read more

BioLumic Pioneers New Seed Traits with Seed Company Partners

August 6, 2024 9:00 AM

BioLumic, the world's only company treating seeds with light to activate genetic expression for new crop traits, has achieved a breakthrough in enhancing inbred corn lines. These genetically 'pure' parent seeds are crucial for producing the world's high-performing hybrid seeds favored by most farmers. After achieving significant performance milestones in 2023 field trials, BioLumic is partnering with Beck's Hybrids, Peterson Corn Genetics,...

Read more

Scorpius Holdings Weighted-Average Pipeline Surpasses $100 Million in Business Develop Opportunities Across Both Manufacturing Client and Government Sectors

August 6, 2024 8:45 AM

Scorpius Holdings, Inc (NYSE American:SCPX), ("Scorpius" or the "Company"), an integrated contract development and manufacturing organization (CDMO), today announced that it has surpassed $100 million in weighted average pipeline of its near-term business development opportunities across both government and manufacturing client sectors. The weighted average pipeline is represented by written proposals which are subject to the execution of...

Read more

OS Therapies Announces Osteosarcoma Scientific and Medical Advisory Board

August 6, 2024 8:35 AM

ROCKVILLE, MD / ACCESSWIRE / August 6, 2024 / OS Therapies (NYSE American:OSTX) ("OS Therapies" or "the Company"), an Antibody Drug Conjugate (ADC) and Immunotherapy research and clinical-stage biopharmaceutical company, highlights its Scientific and Medical Advisory Board (SMAB), comprised of experts in osteosarcoma from six institutions in the United States. The following physicians have agreed to serve on the OS Therapies SMAB: • Nabil M....

Read more

Ondine Biomedical Inc. Announces Leeds Teaching Hospital NHS Trust to use Steriwave

August 6, 2024 2:00 AM

Leeds Teaching Hospitals NHS Trust to use Steriwave VANCOUVER, BC / ACCESSWIRE / August 6, 2024 / Ondine Biomedical Inc. (LON:OBI), the Canadian life sciences company pioneering light-activated antimicrobial treatments, and Iskus Health announce that Leeds Teaching Hospitals NHS Trust will begin using its Steriwave® nasal decolonization technology later this month. Leeds Teaching Hospitals NHS Trust is one of the largest and busiest acute...

Read more

Med-X Poised for Global Expansion and NASDAQ Listing Amidst 200% Revenue Growth

August 5, 2024 9:45 AM

Med-X, the parent company of Nature-Cide, Malibu Brands, and Thermal-Aid - leading natural pesticide and pain-management brands, respectively - is planning a NASDAQ listing in the near future. But they're offering private investors an opportunity to join them before it happens. More than just a pest control and health & wellness product developer, Med-X has an entire portfolio of green products aiming to supply natural solutions that reduce...

Read more

enVVeno Medical Reports Second Quarter 2024 Financial Results and Provides Corporate Update

August 1, 2024 8:05 AM

- Ended the quarter with $39.1 million cash and investments on hand sufficient to fund operations, through the end of 2025, including potential PMA approval of VenoValve® - Positive interim venous ulcer healing data showing significant improvement from the VenoValve pivotal trial presented at the Society for Vascular Surgery 2024 Vascular Annual Meeting - Company on track to file application seeking VenoValve FDA approval in Q4 2024 - Continued...

Read more

Indica Labs Announces Launch of AI-Powered Macrodissection Suite to Advance Molecular Pathology Workflows

August 1, 2024 8:00 AM

Indica Labs, the leading provider of AI-powered digital pathology solutions, proudly announces the launch of Lung Macrodissect AI, a groundbreaking tool that revolutionizes sli­­de macrodissection and molecular pathology workflows. Lung Macrodissect AI represents a significant leap forward for the integration of artificial intelligence with digital pathology by offering pathologists a streamlined macrodissection workflow that minimizes human...

Read more

Vista BioMedical(TM), Inc. Introduces VPAATH(C), an AI-Based Program that Identifies Individual High Risk, High Utilizing Patients Using Social Determinants of Health Factors

July 30, 2024 3:00 PM

ROCHESTER, MN / ACCESSWIRE / July 30, 2024 / Vista BioMedical™, Inc., a medical device and software development company, has launched VPAATH©, a pro-active, predictive AI-based program that can identify individual high risk, high utilizing patients, down to the zip code. VPAATH uses AI analysis for pinpointed SDOH (Social Determinants of Health) factors coupled with individual health risk factors to formulate an overall personalized health...

Read more

BioInvent Receives Notice of Allowance from USPTO for BI-1910 Patent Application

July 30, 2024 9:00 AM

Allowed US patent application for anti-TNFR2 antibody BI-1910 covers composition-of-matter protection and the use of antibody to treat cancer Patent will further strengthen IP protection of BioInvent's innovative portfolio of clinical assets BI-1910 is being studied in a Phase 1/2a trial as both a single agent and in combination with KEYTRUDA® for the treatment of solid tumors LUND, SWEDEN / ACCESSWIRE / July 30, 2024 / BioInvent International...

Read more

Adolore BioTherapeutics Announces Publication of Compelling Preclinical Efficacy and Safety Data Supporting Adolore's Non-opioid Analgesic Gene Therapy, ADLR-1001, For Treatment of Moderate to Severe Chronic Knee Pain Due to Osteoarthritis (OA)

July 30, 2024 8:10 AM

Adolore BioTherapeutics ("Adolore" or the "Company"), a biotechnology company focused on developing breakthrough opioid-free gene therapy treatments for chronic pain, today announced the publication of its manuscript entitled, "Disease-Modifying rdHSV-CA8* Non-Opioid Analgesic Gene Therapy Treats Chronic Osteoarthritis Pain by Activating Kv7 Voltage-Gated Potassium Channels[1], " in the peer-reviewed journal, Frontiers in Molecular Neuroscience....

Read more

AmplifyBio Partners with Industry Leader in Lipid Nanoparticles (LNPs) to Expand Drug Delivery Capabilities

July 30, 2024 7:00 AM

WEST JEFFERSON, OH / ACCESSWIRE / July 30, 2024 / AmplifyBio, an emerging leader among mRNA discovery, development, and manufacturing service providers, announced today that it has formalized a partnership with Stephen Burgess, Ph.D. (AvaBurg LLC), to provide expertise in LNP formulations to ensure efficient encapsulation, protection, and delivery of mRNA to cells. Dr. Burgess formerly served as Chief Scientific Officer at Avanti Polar Lipids....

Read more

Enzolytics, Inc. Enters Into Collaboration Agreement With Manufacturer Elimus Ltd.

July 29, 2024 9:50 AM

Enzolytics, Inc. (OTC PINK:ENZC) ("enzolytics.com")(the "Company") announced today that it has entered into a 4 year Collaboration Agreement with Elimus, Ltd ("Elimus"), a Bulgarian company located in Sofia, for the manufacturing, development and marketing of new and existing nutraceutical products of the two entities. The product license will be for the territory of North America (the United States, Canada and Mexico). The Company will utilize...

Read more

Petros Pharmaceuticals' Pivotal Statistically Significant Self Selection Study Shows Stronger Results with Proprietary Technology Application as Part of FDA Pathway for Over-the-Counter Access for STENDRA(R) (avanafil)

July 29, 2024 9:20 AM

Utilization of the Company's proprietary Web App showed improved self-selection utilizing an embedded validated diagnostic questionnaire compared to a live interview furthering the Company's efforts to potentially create a first-ever Rx-to-OTC switch in the ED category NEW YORK, NY / ACCESSWIRE / July 29, 2024 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) ("Petros" or the "Company"), a company focused on expanding consumer access to medication...

Read more

Lifeloc Technologies, Inc. Appoints Adam Kashenberg to its Board of Directors

July 26, 2024 11:25 AM

Lifeloc Technologies, Inc. (OTC PINK:LCTC) (the "Company"), a global leader in the development and manufacturing of breath alcohol testing devices, has announced the appointment of Adam Kashenberg, president and CEO of Colorado Biolabs, Inc., to its Board of Directors (the "Board"), effective July 23, 2024. "We are pleased to welcome Adam to Lifeloc's board," said Vern Kornelsen, Lifeloc's Chief Financial Officer and Board chair. "Adam is an...

Read more

Enzolytics Inc. Supports Sagaliam Acquisition Corp Response to Competitors False and Misleading Press Release

July 26, 2024 11:00 AM

Enzolytics, Inc. (OTC PINK:ENZC) (enzolytics.com) (the "Company") stated today that the Company will whole heartedly support any and all efforts by Sagaliam Acquisition Corp ("SAGA") in its campaign to stop another attempt by NIKA Pharmaceutical and its CEO, Dimtar Savov, falsely claiming rights to patents issued to Harry H. Zhabilov and the Zhabilov Trust for the Immunotherapy treatment of HIV/AIDS. Mr. Savov has, since defaulting on licensing...

Read more

SOHM, Inc., Announce a New Collaboration and Joins Forces with Stanford University

July 25, 2024 9:30 AM

SOHM, Inc. (OTC PINK:SHMN) (the "Company"), a pharmaceutical and upstart biotechnologycompany that manufactures and markets generic drugs covering numerous treatment categories, announced that it has signed a new agreement with Standford University. In an exciting development, SOHM announces a groundbreaking collaboration of ABBIE Technology with Stanford University, one of the world's leading research institutions. This strategic partnership...

Read more

Palvella Therapeutics and Pieris Pharmaceuticals Announce Definitive Merger Agreement

July 24, 2024 6:30 AM

Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, and Pieris Pharmaceuticals, Inc. (Nasdaq: PIRS) (Pieris) today announced they have entered into a definitive merger agreement to combine the companies in an...

Read more

Tharimmune Appoints Prof. David Jones of Newcastle University to its Scientific Advisory Board

July 22, 2024 8:30 AM

BRIDGEWATER, NJ / ACCESSWIRE / July 22, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, today announced the appointment of David Jones, Professor of Liver Immunology at Newcastle University in England, to its Scientific Advisory Board (SAB). Prof. Jones has earned an international reputation for his work...

Read more